Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases Portfolio News / Karina Tin January 29, 2024 Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases Read More »
Carmot Therapeutics Announces Completion of Acquisition by Roche Portfolio News / Karina Tin January 29, 2024 Carmot Therapeutics Announces Completion of Acquisition by Roche Read More »
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies Portfolio News / Karina Tin January 23, 2024 Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies Read More »
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing Portfolio News / Karina Tin January 22, 2024 ORIC Pharmaceuticals Announces $125 Million Private Placement Financing Read More »
Tr1X Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases Portfolio News / Karina Tin January 17, 2024 Tr1X Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases Read More »
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL Portfolio News / Karina Tin January 16, 2024 Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL Read More »
Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO Portfolio News / Karina Tin January 15, 2024 Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO Read More »
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need Portfolio News / Karina Tin January 9, 2024 NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need Read More »
Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference Portfolio News / Karina Tin January 8, 2024 Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference Read More »
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones Portfolio News / Karina Tin January 8, 2024 ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones Read More »
